2B78:F:F-iShares Healthcare Innovation UCITS ETF USD (Acc) (EUR)

ETF | Others |

Last Closing

USD 7.157

Change

-0.03 (-0.36)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.08 (+0.30%)

USD 139.20B
PRAJ:F Amundi Index Solutions - Amund..

+0.08 (+0.30%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.05 (-0.09%)

USD 115.53B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.05 (-0.09%)

USD 115.53B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 96.59B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 96.59B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 94.63B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 94.63B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 57.94B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 57.94B

ETFs Containing 2B78:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.41% 42% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.41% 38% F 47% F
Trailing 12 Months  
Capital Gain 12.89% 48% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.89% 43% F 50% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -7.10% N/A N/A 27% F
Dividend Return -7.10% N/A N/A 25% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.07% N/A N/A 86% B+
Risk Adjusted Return -64.16% N/A N/A 18% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike